Recursion Pharmaceuticals Inc is trading 10.4% down at $3.40 amid broad risk-off pressure hitting high-growth biotech and tech names.
- The decline follows stronger-than-expected U.S. jobs data, which has fueled rising doubts regarding the timing of future interest rate cuts.
- There are no fresh company-specific headlines, clinical updates, or rating changes to account for today's move.
- Recent coverage indicates the drop is tied to sector-wide weakness in growth-sensitive assets rather than new fundamental developments for the company.